Which of the following is an exclusive 5-HT 1F receptor agonist approved by FDA for treatment of acute migraine attack?
Rimegepant
Lasmiditan
Eletriptan
Dosulepin
Lasmiditan has been approved by FDA in October 2019 for acute treatment of migraine attack which is a selective 5-HT 1F receptor agonist. The triptans were designed to stimulate selectively subpopulations of 5-HT receptors; at least 14 different 5-HT receptors exist in humans. The triptans are potent agonists of 5-HT1B and 5-HT1D receptors, and some are active at the 5-HT1F receptor; the latter's exclusive agonists are called ditans. Most drugs effective in the treatment of migraine are members of one of three major pharmacologic classes: nonsteroidal anti-inflammatory drugs, 5-HT1B/1D receptor agonists, and dopamine receptor antagonists. Two new classes of therapeutic agents, CGRP receptor antagonists, such as rimegepant and ubrogepant, and 5-HT1F receptor agonists, such as lasmiditan, should soon be available. Ref Harrison 20th edition page 3096, 3100.
C.N.S